{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:41:56Z","timestamp":1794246116827,"version":"4.9.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Biomed. Eng"],"DOI":"10.1038\/s41551-026-01661-3","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T09:01:59Z","timestamp":1776934919000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pre-intervention with intravenous immunoglobulin reverses the immunogenic clearance of PEGylated nanomedicines"],"prefix":"10.1038","author":[{"given":"Keren","family":"Lai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuejian","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guifeng","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqiu","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5142-8264","authenticated-orcid":false,"given":"Xiaorui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,23]]},"reference":[{"key":"1661_CR1","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/nbt.3330","volume":"33","author":"E Blanco","year":"2015","unstructured":"Blanco, E., Shen, H. & Ferrari, M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat. Biotechnol. 33, 941\u2013951 (2015).","journal-title":"Nat. Biotechnol."},{"key":"1661_CR2","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1038\/s41563-021-01047-7","volume":"20","author":"I de L\u00e1zaro","year":"2021","unstructured":"de L\u00e1zaro, I. & Mooney, D. J. Obstacles and opportunities in a forward vision for cancer nanomedicine. Nat. Mater. 20, 1469\u20131479 (2021).","journal-title":"Nat. Mater."},{"key":"1661_CR3","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/nmat4718","volume":"15","author":"KM Tsoi","year":"2016","unstructured":"Tsoi, K. M. et al. Mechanism of hard-nanomaterial clearance by the liver. Nat. Mater. 15, 1212\u20131221 (2016).","journal-title":"Nat. Mater."},{"key":"1661_CR4","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jconrel.2017.01.024","volume":"259","author":"S-B Yong","year":"2017","unstructured":"Yong, S.-B., Song, Y., Kim, H. J., Ain, Q. U. & Kim, Y.-H. Mononuclear phagocytes as a target, not a barrier, for drug delivery. J. Control. Release 259, 53\u201361 (2017).","journal-title":"J. Control. Release"},{"key":"1661_CR5","doi-asserted-by":"crossref","unstructured":"Zelepukin, I. V., Shevchenko, K. G. & Deyev, S. M. Rediscovery of mononuclear phagocyte system blockade for nanoparticle drug delivery. Nat. Commun. 15, 4366 (2024).","DOI":"10.1038\/s41467-024-48838-5"},{"key":"1661_CR6","doi-asserted-by":"crossref","unstructured":"Guo, C. et al. The interplay between PEGylated nanoparticles and blood immune system. Adv. Drug Deliv. Rev. 200, 115044 (2023).","DOI":"10.1016\/j.addr.2023.115044"},{"key":"1661_CR7","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","volume":"99","author":"JS Suk","year":"2016","unstructured":"Suk, J. S., Xu, Q., Kim, N., Hanes, J. & Ensign, L. M. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv. Drug Deliv. Rev. 99, 28\u201351 (2016).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"1661_CR8","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.medj.2022.12.001","volume":"4","author":"P Zhang","year":"2023","unstructured":"Zhang, P. et al. Cancer nanomedicine toward clinical translation: obstacles, opportunities, and future prospects. Med 4, 147\u2013167 (2023).","journal-title":"Med"},{"key":"1661_CR9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jconrel.2023.09.003","volume":"363","author":"G Miao","year":"2023","unstructured":"Miao, G. et al. Accelerated blood clearance of PEGylated nanoparticles induced by PEG-based pharmaceutical excipients. J. Control. Release 363, 12\u201326 (2023).","journal-title":"J. Control. Release"},{"key":"1661_CR10","doi-asserted-by":"crossref","unstructured":"Fu, J., Wu, E., Li, G., Wang, B. & Zhan, C. Anti-PEG antibodies: current situation and countermeasures. Nano Today 55, 102163 (2024).","DOI":"10.1016\/j.nantod.2024.102163"},{"key":"1661_CR11","doi-asserted-by":"crossref","unstructured":"Shi, D. et al. To PEGylate or not to PEGylate: immunological properties of nanomedicine\u2019s most popular component, polyethylene glycol and its alternatives. Adv. Drug Deliv. Rev. 180, 114079 (2022).","DOI":"10.1016\/j.addr.2021.114079"},{"key":"1661_CR12","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41573-023-00859-3","volume":"23","author":"D Bitounis","year":"2024","unstructured":"Bitounis, D., Jacquinet, E., Rogers, M. A. & Amiji, M. M. Strategies to reduce the risks of mRNA drug and vaccine toxicity. Nat. Rev. Drug Discov. 23, 281\u2013300 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1661_CR13","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1056\/NEJMra2035343","volume":"384","author":"MC Castells","year":"2021","unstructured":"Castells, M. C., Longo, D. L. & Phillips, E. J. Maintaining safety with SARS-CoV-2 vaccines. N. Engl. J. Med. 384, 643\u2013649 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1661_CR14","doi-asserted-by":"publisher","first-page":"11769","DOI":"10.1021\/acsnano.2c04543","volume":"16","author":"Y Ju","year":"2022","unstructured":"Ju, Y. et al. Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine. ACS Nano 16, 11769\u201311780 (2022).","journal-title":"ACS Nano"},{"key":"1661_CR15","doi-asserted-by":"publisher","first-page":"23814","DOI":"10.1021\/acsnano.3c07932","volume":"17","author":"X Yu","year":"2023","unstructured":"Yu, X. et al. Poly(ethyl ethylene phosphate): overcoming the \u201cpolyethylene glycol dilemma\u201d for cancer immunotherapy and mRNA vaccination. ACS Nano 17, 23814\u201323828 (2023).","journal-title":"ACS Nano"},{"key":"1661_CR16","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.addr.2020.07.024","volume":"154\u2013155","author":"GT Kozma","year":"2020","unstructured":"Kozma, G. T., Shimizu, T., Ishida, T. & Szebeni, J. Anti-PEG antibodies: properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals. Adv. Drug Deliv. Rev. 154\u2013155, 163\u2013175 (2020).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"1661_CR17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jconrel.2013.07.026","volume":"172","author":"AS Abu Lila","year":"2013","unstructured":"Abu Lila, A. S., Kiwada, H. & Ishida, T. The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage. J. Control. Release 172, 38\u201347 (2013).","journal-title":"J. Control. Release"},{"key":"1661_CR18","doi-asserted-by":"crossref","unstructured":"Ehlinger, C., Spear, N., Doddareddy, R., Shankar, G. & Schantz, A. A generic method for the detection of polyethylene glycol specific IgG and IgM antibodies in human serum. J. Immunol. Methods 474, 112669 (2019).","DOI":"10.1016\/j.jim.2019.112669"},{"key":"1661_CR19","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s40883-021-00198-y","volume":"8","author":"H Freire Haddad","year":"2021","unstructured":"Freire Haddad, H., Burke, J. A., Scott, E. A. & Ameer, G. A. Clinical relevance of pre-existing and treatment-induced anti-poly(ethylene glycol) antibodies. Regen. Eng. Transl. Med. 8, 32\u201342 (2021).","journal-title":"Regen. Eng. Transl. Med."},{"key":"1661_CR20","doi-asserted-by":"publisher","first-page":"10661","DOI":"10.1021\/acs.analchem.6b03109","volume":"88","author":"B-M Chen","year":"2016","unstructured":"Chen, B.-M. et al. Measurement of pre-existing IgG and IgM antibodies against polyethylene glycol in healthy individuals. Anal. Chem. 88, 10661\u201310666 (2016).","journal-title":"Anal. Chem."},{"key":"1661_CR21","doi-asserted-by":"crossref","unstructured":"Han, X. et al. Polysialic acid modified liposomes for improving pharmacokinetics and overcoming accelerated blood clearance phenomenon. Coatings 10, 834 (2020).","DOI":"10.3390\/coatings10090834"},{"key":"1661_CR22","doi-asserted-by":"crossref","unstructured":"Sun, J. et al. Evaluation of the antitumor effect and immune response of micelles modified with a polysialic acid-d-\u03b1-tocopheryl polyethylene glycol 1000 succinate conjugate. AAPS PharmSciTech 22, 223 (2021).","DOI":"10.1208\/s12249-021-02047-1"},{"key":"1661_CR23","doi-asserted-by":"publisher","first-page":"18419","DOI":"10.1021\/jacs.2c06877","volume":"144","author":"Y Tian","year":"2022","unstructured":"Tian, Y. et al. Engineering poly(ethylene glycol) nanoparticles for accelerated blood clearance inhibition and targeted drug delivery. J. Am. Chem. Soc. 144, 18419\u201318428 (2022).","journal-title":"J. Am. Chem. Soc."},{"key":"1661_CR24","doi-asserted-by":"crossref","unstructured":"Liu, M. et al. Branched PEG-modification: a new strategy for nanocarriers to evade of the accelerated blood clearance phenomenon and enhance anti-tumor efficacy. Biomaterials 283, 121415 (2022).","DOI":"10.1016\/j.biomaterials.2022.121415"},{"key":"1661_CR25","doi-asserted-by":"publisher","first-page":"5654","DOI":"10.1021\/acs.biomac.3c00649","volume":"24","author":"P Khunsuk","year":"2023","unstructured":"Khunsuk, P., Pongma, C., Palaga, T. & Hoven, V. P. Zwitterionic polymer-decorated lipid nanoparticles for mRNA delivery in mammalian cells. Biomacromolecules 24, 5654\u20135665 (2023).","journal-title":"Biomacromolecules"},{"key":"1661_CR26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jconrel.2023.10.023","volume":"364","author":"J Xia","year":"2023","unstructured":"Xia, J. et al. Ginsenoside Rg3 endows liposomes with prolonged blood circulation and reduced accelerated blood clearance. J. Control. Release 364, 23\u201336 (2023).","journal-title":"J. Control. Release"},{"key":"1661_CR27","first-page":"86","volume":"37","author":"DD Kang","year":"2024","unstructured":"Kang, D. D. et al. Engineering LNPs with polysarcosine lipids for mRNA delivery. Bioact. Mater. 37, 86\u201393 (2024).","journal-title":"Bioact. Mater."},{"key":"1661_CR28","doi-asserted-by":"crossref","unstructured":"Xiao, Y. et al. High-density brush-shaped polymer lipids reduce anti-PEG antibody binding for repeated administration of mRNA therapeutics. Nat. Mater. 24, 1840\u20131851 (2025).","DOI":"10.1038\/s41563-024-02116-3"},{"key":"1661_CR29","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00418-022-02086-0","volume":"157","author":"AM Abu-Dief","year":"2022","unstructured":"Abu-Dief, A. M., Alsehli, M. & Awaad, A. A higher dose of PEGylated gold nanoparticles reduces the accelerated blood clearance phenomenon effect and induces spleen B lymphocytes in albino mice. Histochem. Cell Biol. 157, 641\u2013656 (2022).","journal-title":"Histochem. Cell Biol."},{"key":"1661_CR30","first-page":"455","volume":"14","author":"C Lai","year":"2019","unstructured":"Lai, C. et al. Effect of Kupffer cells depletion on ABC phenomenon induced by Kupffer cells-targeted liposomes. Asian J. Pharm. Sci. 14, 455\u2013464 (2019).","journal-title":"Asian J. Pharm. Sci."},{"key":"1661_CR31","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ijpharm.2012.08.030","volume":"438","author":"AS Abu Lila","year":"2012","unstructured":"Abu Lila, A. S., Eldin, N. E., Ichihara, M., Ishida, T. & Kiwada, H. Multiple administration of PEG-coated liposomal oxaliplatin enhances its therapeutic efficacy: a possible mechanism and the potential for clinical application. Int. J. Pharm. 438, 176\u2013183 (2012).","journal-title":"Int. J. Pharm."},{"key":"1661_CR32","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jconrel.2019.08.017","volume":"311-312","author":"MD McSweeney","year":"2019","unstructured":"McSweeney, M. D. et al. Overcoming anti-PEG antibody mediated accelerated blood clearance of PEGylated liposomes by pre-infusion with high molecular weight free PEG. J. Control. Release 311-312, 138\u2013146 (2019).","journal-title":"J. Control. Release"},{"key":"1661_CR33","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/nri3401","volume":"13","author":"I Schwab","year":"2013","unstructured":"Schwab, I. & Nimmerjahn, F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat. Rev. Immunol. 13, 176\u2013189 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"1661_CR34","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1126\/science.1154315","volume":"320","author":"RM Anthony","year":"2008","unstructured":"Anthony, R. M. et al. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 320, 373\u2013376 (2008).","journal-title":"Science"},{"key":"1661_CR35","doi-asserted-by":"crossref","unstructured":"Li, H. et al. Spatiotemporal transcriptomics elucidates the pathogenesis of fulminant viral myocarditis. Signal Transduct. Target. Ther. 10, 59 (2025).","DOI":"10.1038\/s41392-025-02143-9"},{"key":"1661_CR36","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1517\/14740338.1.2.153","volume":"1","author":"Y Sherer","year":"2005","unstructured":"Sherer, Y., Levy, Y. & Shoenfeld, Y. IVIG in autoimmunity and cancer\u2014efficacy versus safety. Expert Opin. Drug Saf. 1, 153\u2013158 (2005).","journal-title":"Expert Opin. Drug Saf."},{"key":"1661_CR37","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1385\/CRIAI:29:3:307","volume":"29","author":"T Sapir","year":"2005","unstructured":"Sapir, T. & Shoenfeld, Y. Uncovering the hidden potential of intravenous immunoglobulin as an anticancer therapy. Clin. Rev. Allergy Immunol. 29, 307\u2013310 (2005).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"1661_CR38","doi-asserted-by":"crossref","unstructured":"Merimsky, O. et al. A possible role for IVIg in the treatment of soft tissue sarcoma: a clinical case and an experimental model. Int. J. Oncol. 20, 839\u2013843 (2002).","DOI":"10.3892\/ijo.20.4.839"},{"key":"1661_CR39","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S2213-2600(21)00353-2","volume":"10","author":"I Psallidas","year":"2022","unstructured":"Psallidas, I. et al. Role of thoracic ultrasonography in pleurodesis pathways for malignant pleural effusions (SIMPLE): an open-label, randomised controlled trial. Lancet Respir. Med. 10, 139\u2013148 (2022).","journal-title":"Lancet Respir. Med."},{"key":"1661_CR40","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1136\/annrheumdis-2020-219725","volume":"80","author":"A Alunno","year":"2021","unstructured":"Alunno, A. et al. Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider. Ann. Rheum. Dis. 80, 803\u2013815 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"1661_CR41","doi-asserted-by":"publisher","first-page":"3302","DOI":"10.1002\/eji.201242710","volume":"42","author":"I Schwab","year":"2012","unstructured":"Schwab, I. et al. B cells and CD22 are dispensable for the immediate antiinflammatory activity of intravenous immunoglobulins in vivo. Eur. J. Immunol. 42, 3302\u20133309 (2012).","journal-title":"Eur. J. Immunol."},{"key":"1661_CR42","doi-asserted-by":"publisher","first-page":"19571","DOI":"10.1073\/pnas.0810163105","volume":"105","author":"RM Anthony","year":"2008","unstructured":"Anthony, R. M., Wermeling, F., Karlsson, M. C. I. & Ravetch, J. V. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc. Natl Acad. Sci. USA 105, 19571\u201319578 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1661_CR43","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1182\/blood-2014-05-576835","volume":"124","author":"SQ Nagelkerke","year":"2014","unstructured":"Nagelkerke, S. Q. et al. Inhibition of Fc\u03b3R-mediated phagocytosis by IVIg is independent of IgG-Fc sialylation and Fc\u03b3RIIb in human macrophages. Blood 124, 3709\u20133718 (2014).","journal-title":"Blood"},{"key":"1661_CR44","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1146\/annurev.immunol.26.021607.090232","volume":"26","author":"F Nimmerjahn","year":"2008","unstructured":"Nimmerjahn, F. & Ravetch, J. V. Anti-inflammatory actions of intravenous immunoglobulin. Annu. Rev. Immunol. 26, 513\u2013533 (2008).","journal-title":"Annu. Rev. Immunol."},{"key":"1661_CR45","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.it.2008.08.004","volume":"29","author":"T Tha-In","year":"2008","unstructured":"Tha-In, T., Bayry, J., Metselaar, H. J., Kaveri, S. V. & Kwekkeboom, J. Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol. 29, 608\u2013615 (2008).","journal-title":"Trends Immunol."},{"key":"1661_CR46","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.nano.2016.01.013","volume":"12","author":"J-K Park","year":"2016","unstructured":"Park, J.-K. et al. Cellular distribution of injected PLGA-nanoparticles in the liver. Nanomedicine 12, 1365\u20131374 (2016).","journal-title":"Nanomedicine"},{"key":"1661_CR47","doi-asserted-by":"publisher","first-page":"10130","DOI":"10.1021\/acsnano.8b04947","volume":"12","author":"H Zhou","year":"2018","unstructured":"Zhou, H. et al. Dense and dynamic polyethylene glycol shells cloak nanoparticles from uptake by liver endothelial cells for long blood circulation. ACS Nano 12, 10130\u201310141 (2018).","journal-title":"ACS Nano"},{"key":"1661_CR48","doi-asserted-by":"crossref","unstructured":"Chen, T. et al. Morphology-driven protein corona manipulation for preferential delivery of lipid nanodiscs. Nano Today 46, 101609 (2022).","DOI":"10.1016\/j.nantod.2022.101609"},{"key":"1661_CR49","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1084\/jem.20021801","volume":"198","author":"MA Nolte","year":"2003","unstructured":"Nolte, M. A. et al. A conduit system distributes chemokines and small blood-borne molecules through the splenic white pulp. J. Exp. Med. 198, 505\u2013512 (2003).","journal-title":"J. Exp. Med."},{"key":"1661_CR50","doi-asserted-by":"publisher","first-page":"4234","DOI":"10.4049\/jimmunol.146.12.4234","volume":"146","author":"A Chonn","year":"1991","unstructured":"Chonn, A., Cullis, P. R. & Devine, D. V. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. J. Immunol. 146, 4234\u20134241 (1991).","journal-title":"J. Immunol."},{"key":"1661_CR51","doi-asserted-by":"publisher","first-page":"7604","DOI":"10.1021\/jacs.4c16987","volume":"147","author":"D Baimanov","year":"2025","unstructured":"Baimanov, D. et al. Identification of cell receptors responsible for recognition and binding of lipid nanoparticles. J. Am. Chem. Soc. 147, 7604\u20137616 (2025).","journal-title":"J. Am. Chem. Soc."},{"key":"1661_CR52","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41590-022-01160-y","volume":"23","author":"S Tahtinen","year":"2022","unstructured":"Tahtinen, S. et al. IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. Nat. Immunol. 23, 532\u2013542 (2022).","journal-title":"Nat. Immunol."},{"key":"1661_CR53","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/nri2711","volume":"10","author":"M Saraiva","year":"2010","unstructured":"Saraiva, M. & O\u2019Garra, A. The regulation of IL-10 production by immune cells. Nat. Rev. Immunol. 10, 170\u2013181 (2010).","journal-title":"Nat. Rev. Immunol."},{"key":"1661_CR54","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1021\/acs.bioconjchem.8b00912","volume":"30","author":"AWL Kinman","year":"2019","unstructured":"Kinman, A. W. L. & Pompano, R. R. Optimization of enzymatic antibody fragmentation for yield, efficiency, and binding affinity. Bioconjug. Chem. 30, 800\u2013807 (2019).","journal-title":"Bioconjug. Chem."},{"key":"1661_CR55","doi-asserted-by":"publisher","first-page":"122396","DOI":"10.1016\/j.jchromb.2020.122396","volume":"1158","author":"C Armutcu","year":"2020","unstructured":"Armutcu, C., \u00c7orman, M. E., Bayram, E. & Uzun, L. Purification of Fab and Fc using papain immobilized cryogel bioreactor separator system. J. Chromatogr. B 1158, 122396 (2020).","journal-title":"J. Chromatogr. B"},{"key":"1661_CR56","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41565-021-00856-w","volume":"16","author":"M Cao","year":"2021","unstructured":"Cao, M. et al. Molybdenum derived from nanomaterials incorporates into molybdenum enzymes and affects their activities in vivo. Nat. Nanotechnol. 16, 708\u2013716 (2021).","journal-title":"Nat. Nanotechnol."},{"key":"1661_CR57","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/s41563-023-01515-2","volume":"22","author":"S Shin","year":"2023","unstructured":"Shin, S. et al. Curvature-sensing peptide inhibits tumour-derived exosomes for enhanced cancer immunotherapy. Nat. Mater. 22, 656\u2013665 (2023).","journal-title":"Nat. Mater."},{"key":"1661_CR58","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1038\/s43018-025-00997-0","volume":"6","author":"G Miao","year":"2025","unstructured":"Miao, G. et al. Concurrent inhibition of tumor growth and metastasis by a lipidated nanophotosensitizer tracing and disabling tumor extracellular vesicles. Nat. Cancer 6, 1438\u20131457 (2025).","journal-title":"Nat. Cancer"},{"key":"1661_CR59","doi-asserted-by":"publisher","first-page":"D543","DOI":"10.1093\/nar\/gkae1011","volume":"53","author":"Y Perez-Riverol","year":"2025","unstructured":"Perez-Riverol, Y. et al. The PRIDE database at 20 years: 2025 update. Nucleic Acids Res. 53, D543\u2013D553 (2025).","journal-title":"Nucleic Acids Res."},{"key":"1661_CR60","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1158\/2767-9764.CRC-23-0243","volume":"3","author":"B Mao","year":"2023","unstructured":"Mao, B. & Guo, S. Statistical assessment of drug synergy from in vivo combination studies using mouse tumor models. Cancer Res. Commun. 3, 2146\u20132157 (2023).","journal-title":"Cancer Res. Commun."}],"container-title":["Nature Biomedical Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41551-026-01661-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-026-01661-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-026-01661-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T09:02:11Z","timestamp":1776934931000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41551-026-01661-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":60,"alternative-id":["1661"],"URL":"https:\/\/doi.org\/10.1038\/s41551-026-01661-3","relation":{},"ISSN":["2157-846X"],"issn-type":[{"value":"2157-846X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,23]]},"assertion":[{"value":"12 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}